Overview A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine Status: Completed Trial end date: 2019-01-18 Target enrollment: Participant gender: Summary The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine. Phase: Phase 2 Details Lead Sponsor: Eli Lilly and Company